貝達藥業(300558.SZ)擬10億元投建創新藥產業化(嵊州)基地項目
格隆匯 9 月 29日丨貝達藥業(300558.SZ)公佈,公司(“乙方”)系一家集醫藥研發、生產營銷於一體的國家級高新技術企業,目前已上市產品為鹽酸埃克替尼(商品名:凱美納®),研發管線中有多個品種處於後期臨牀試驗階段,即將獲批上市或即將申報上市。公司現有產業基地空間及環保、安全設施建設已不能滿足公司未來新產品的製造需求。
2020年9月29日,公司召開第三屆董事會第十一次會議,審議通過了《關於簽訂創新藥產業化(嵊州)基地項目投資協議書的議案》,同意公司與嵊州市人民政府(“甲方”)簽訂《創新藥產業化(嵊州)基地項目投資協議書》,預計項目總投資為人民幣10億元。公司管理層將盡快協調完成協議的簽署工作。
項目名稱:創新藥產業化(嵊州)基地;項目用途:生產和儲運多個即將投入生產的新產品以及後續提交上市品種;項目地址:嵊州經濟開發區城北區塊,總面積約215畝,宗地性質為工業用地。
該協議為意向性框架協議,協議所涉及的項目投資額為10億元人民幣,該金額為假設全部相關項目均獲核准併成功實施情況下的初步預算,實際投資金額尚存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.